JP2009221186A5 - - Google Patents

Download PDF

Info

Publication number
JP2009221186A5
JP2009221186A5 JP2008238844A JP2008238844A JP2009221186A5 JP 2009221186 A5 JP2009221186 A5 JP 2009221186A5 JP 2008238844 A JP2008238844 A JP 2008238844A JP 2008238844 A JP2008238844 A JP 2008238844A JP 2009221186 A5 JP2009221186 A5 JP 2009221186A5
Authority
JP
Japan
Prior art keywords
composition
composition according
weight percent
acyclovir
alkanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008238844A
Other languages
English (en)
Japanese (ja)
Other versions
JP4972062B2 (ja
JP2009221186A (ja
Filing date
Publication date
Application filed filed Critical
Priority to US12/403,665 priority Critical patent/US20090270429A1/en
Priority to PCT/EP2009/053125 priority patent/WO2009115510A1/en
Priority to EP09723439A priority patent/EP2278956B1/en
Priority to AT09723439T priority patent/ATE525063T1/de
Priority to MX2010010089A priority patent/MX2010010089A/es
Priority to CA2717440A priority patent/CA2717440C/en
Priority to ES09723439T priority patent/ES2372149T3/es
Publication of JP2009221186A publication Critical patent/JP2009221186A/ja
Publication of JP2009221186A5 publication Critical patent/JP2009221186A5/ja
Application granted granted Critical
Publication of JP4972062B2 publication Critical patent/JP4972062B2/ja
Priority to US15/064,711 priority patent/US20170020882A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008238844A 2008-03-17 2008-09-18 抗ウイルス製剤 Expired - Fee Related JP4972062B2 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/403,665 US20090270429A1 (en) 2008-03-17 2009-03-13 Antiviral formulation
EP09723439A EP2278956B1 (en) 2008-03-17 2009-03-17 Antiviral formulation
AT09723439T ATE525063T1 (de) 2008-03-17 2009-03-17 Antivirale formulierung
MX2010010089A MX2010010089A (es) 2008-03-17 2009-03-17 Formulacion antiviral.
PCT/EP2009/053125 WO2009115510A1 (en) 2008-03-17 2009-03-17 Antiviral formulation
CA2717440A CA2717440C (en) 2008-03-17 2009-03-17 Antiviral formulation
ES09723439T ES2372149T3 (es) 2008-03-17 2009-03-17 Formulación antivírica.
US15/064,711 US20170020882A1 (en) 2008-03-17 2016-03-09 Antiviral formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152862 2008-03-17
EP08152862.2 2008-03-17

Publications (3)

Publication Number Publication Date
JP2009221186A JP2009221186A (ja) 2009-10-01
JP2009221186A5 true JP2009221186A5 (enExample) 2011-10-13
JP4972062B2 JP4972062B2 (ja) 2012-07-11

Family

ID=39343655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008238844A Expired - Fee Related JP4972062B2 (ja) 2008-03-17 2008-09-18 抗ウイルス製剤

Country Status (8)

Country Link
US (2) US20090270429A1 (enExample)
EP (1) EP2278956B1 (enExample)
JP (1) JP4972062B2 (enExample)
AT (1) ATE525063T1 (enExample)
CA (1) CA2717440C (enExample)
ES (1) ES2372149T3 (enExample)
MX (1) MX2010010089A (enExample)
WO (1) WO2009115510A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100100060A1 (en) * 2008-10-17 2010-04-22 Novartis Ag Applicator for pharmaceutical product and method of using same
EP2335690A1 (en) 2009-12-09 2011-06-22 BioAlliance Pharma Mucoadhesive buccal tablets for the treatment of orofacial herpes
DK2509586T3 (en) 2009-12-09 2018-08-06 Vectans Pharma MUCOADHASIVE BUCHALT TABLETS FOR THE TREATMENT OF OROFACIAL HERPES
KR20140024292A (ko) 2011-04-01 2014-02-28 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 치료제의 국소 전달용 감열성, 점막부착성 또는 표피부착성, 및 침투강화성 제제
ITMI20111747A1 (it) * 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
EP3337512A1 (en) * 2015-08-17 2018-06-27 Sanovel Ilac Sanayi ve Ticaret A.S. A topical antiviral composition
RU2672878C1 (ru) * 2017-12-13 2018-11-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) Анальгезирующее и противовирусное средство на основе 2,2'-[(6-метилпиримидин-2,4-диил)бис(3-(4-нитрофенил)-1H-1,2,4-триазол-1,5-диил)]дипропановой кислоты

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830005852A (ko) * 1980-07-18 1983-09-14 미첼 페터 잭슨 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
GB8815241D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Antiviral combinations & compounds therefor
GB9315755D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized formulation
TW438585B (en) * 1995-02-06 2001-06-07 Astra Ab Pharmaceutical compositions for topical administration for prophylaxis and/or treatment of herpesvirus infections
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
GB9718791D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Medicaments
US7223387B2 (en) * 1998-11-18 2007-05-29 Medivir Ab Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
SE9803929D0 (sv) * 1998-11-18 1998-11-18 Medivir Ab Antiviral formulation

Similar Documents

Publication Publication Date Title
JP2009221186A5 (enExample)
Mathé et al. L-nucleoside enantiomers as antivirals drugs: a mini-review
ES2214528T3 (es) Composicion farmaceutica para aplicacion topica que contiene aciclovir e hidrocortisona.
UY27875A1 (es) Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
ES2533206T3 (es) Inhibidores de PDE7 para uso en el tratamiento de trastornos del movimiento
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
HRP20151000T1 (hr) Antivirusni spojevi
BR0313424A (pt) Forma de dosagem e processo para a preparação de uma forma de dosagem
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
HRP20150375T1 (hr) Derivati piridazinona
JP2002518321A5 (enExample)
JP2003519659A5 (enExample)
Leung et al. Herpes labialis: an update
HRP20131233T1 (hr) Terapeutski sastav koji obuhvaä†a specifiäśni antagonist receptora endotelina i pde5-inhibitor
JP2014001235A5 (enExample)
JP2013534228A5 (enExample)
JP2005068010A5 (enExample)
HRP20140326T1 (hr) Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat
Silva-Alvarez et al. Herpes labialis: a new possibility for topical treatment with well-elucidated drugs
HRP20210010T1 (hr) Injekcijske farmaceutske formulacije lefamulina
ES2272689T3 (es) Dihidro-triterpenos en el tratamiento de infecciones virales, enfermedad cardiovascular, inflamacion, hipersensibilidad o dolor.
JP2008088189A5 (enExample)
RU2010107177A (ru) Новые комбинации нерамексана для лечения нейродегенеративных расстройств